Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. Cathal also provides some news on the Genomic Database and explains how he expects hVIVO to make a profit.
Home » Open Orphan (ORPH) » Cathal Friel, Open Orphan #ORPH CEO confirms to Proactive Investors that the hVIVO deal is done